Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 8150 results

  1. Momelotinib for treating myelofibrosis-related splenomegaly or symptoms [ID6141]

    In development [GID-TA11064] Expected publication date: 20 March 2024

  2. Ovarian cancer: identifying and managing familial and genetic risk

    In development [GID-NG10225] Expected publication date: 20 March 2024

  3. Nirmatrelvir plus ritonavir for treating COVID-19 (Partial Rapid Review of TA878) [ID6262]

    In development [GID-TA11324] Expected publication date: 13 March 2024

  4. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer

    In development [GID-IPG10291] Expected publication date: 13 March 2024

  5. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment

    In development [GID-HTE10020] Expected publication date: 25 March 2024

  6. Overweight and obesity management

    In development [GID-NG10182] Expected publication date: 27 March 2024

  7. Kurin Lock for blood culture collection

    In development [GID-MT582] Expected publication date: 27 March 2024

  8. GID-MT575 GaitSmart rehabilitation exercise programme for gait and mobility issues

    In development [GID-MT575] Expected publication date: 27 March 2024

  9. Ritlecitinib for treating severe alopecia areata in people 12 years and over [ID4007]

    In development [GID-TA11037] Expected publication date: 27 March 2024

  10. Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]

    In development [GID-TA10656] Expected publication date: 27 March 2024

  11. Twin and triplet pregnancy - progesterone for preventing preterm birth

    In development [GID-NG10383] Expected publication date: 28 March 2024

  12. Asthma: diagnosis, monitoring and chronic asthma management

    In development [GID-NG10186] Expected publication date: 30 October 2024

  13. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3968]

    In development [GID-TA10850] Expected publication date: 03 April 2024

  14. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]

    In development [GID-TA10813] Expected publication date: 03 April 2024